Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sarabesin 3
- Development stage
- Unknown
- Lead developer
- Erasmus MC
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Sarabesin 3 (SB3) is a radiolabeled peptide-based imaging agent designed as a gastrin-releasing peptide receptor (GRPR) antagonist. Developed primarily by Erasmus MC (Universitair Medisch Centrum Rotterdam), it is typically labeled with the positron-emitting radionuclide gallium-68 (68Ga) for use in positron emission tomography (PET) imaging. The agent targets the GRPR, which is frequently overexpressed in various malignancies, including prostate and breast cancers. As an antagonist, Sarabesin 3 binds to the receptor without triggering a biological response, potentially offering a better safety profile and imaging contrast compared to earlier agonist-based tracers. It has been evaluated in clinical studies for the detection, staging, and intra-operative guidance of GRPR-expressing tumors.
- Other names
- gallium-68-labelled Sarabesin 3gallium68-labelled Sarabesin 3gallium 68-labelled Sarabesin 368Ga-Sarabesin 3
02
Targets
GRPR (Gastrin-releasing peptide receptor)BRS3 (Bombesin receptor subtype 3)NMBR (Neuromedin B receptor)
Beyond the preview
Go deeper on sarabesin 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sarabesin 3.